Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present....
Main Authors: | T. V. Ashcheulova, K. M. Kompaniiets, N. M. Herasimchuk |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaporozhye State Medical University
2019-12-01
|
Series: | Patologìâ |
Subjects: | |
Online Access: | http://pat.zsmu.edu.ua/article/view/188964/189447 |
Similar Items
-
Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
by: Reza Mohebi, et al.
Published: (2023-04-01) -
Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01) -
First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01) -
Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01) -
Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023-01-01)